Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases.

Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company focused on synaptic health and restoration in neurodegenerative disorders through a pipeline of disease modifying small molecule drug candidates.

i-Lumen Scientific, Inc. is a medical company developing a next-generation, non-invasive, transpalpebral microcurrent electrical stimulation device to treat patients with visual acuity loss due to retinal degeneration.

Immusoft Corporation’s (immusoft.com) mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs the cells to produce gene-encoded medicines (biologics) for rare genetic diseases.

IN8bio (NASDAQ: INAB) is a clinical-stage immune-oncology company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer.

Lantern Pharma (NASDAQ: LTRN) is a clinical stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. Lantern leverages advances in machine learning, genomics and artificial intelligence to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics.

Lung Therapeutics is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs.

ONL Therapeutics is a clinical staged company with a novel approach to preserving sight and halting vision loss associated with a range of retinal disease. The company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the Fas pathway.

Opus Genetics is a preclinical company developing ocular AAV gene therapies to address a large pipeline of rare genetic blinding conditions that have no current treatment options.

SIRPant Immunotherapeutics is a preclinical immuno-oncology company developing an innovative, enhanced macrophage cell therapy platform for the treatment of a broad range of solid tumors by facilitating the activation of the patient's own immune system.

Stream Biomedical is a preclinical biotechnology company focused on leveraging its engineered perlecan domain V to develop first-in-class treatments for serious neurogenerative disorders such as stroke.

Trefoil Therapeutics is a preclinical biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders.

Encore Vision is a clinical-stage subsidiary of Novartis that is developing novel small molecule therapies for the topical treatment of presbyopia, a condition of worsening vision due to aging.

Taysha Gene Therapies (NASDAQ: TSHA) is a clinical staged company focused on the treatment of monogenic CNS disease. Taysha is advancing an extensive AAV gene therapy pipeline, with lead candidates in GM2 gangliosidosis, Rett syndrome, and CLN1.